The estimated Net Worth of Richard A. Jr. Zordani is at least $87.9 Tysiąc dollars as of 22 August 2024. Mr. Zordani owns over 3,500 units of Galectin Therapeutics Inc stock worth over $87,907 and over the last 4 years he sold GALT stock worth over $0. In addition, he makes $0 as Independent Director at Galectin Therapeutics Inc.
Richard has made over 5 trades of the Galectin Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 3,500 units of GALT stock worth $8,050 on 22 August 2024.
The largest trade he's ever made was buying 5,000 units of Galectin Therapeutics Inc stock on 28 July 2022 worth over $12,500. On average, Richard trades about 2,167 units every 106 days since 2021. As of 22 August 2024 he still owns at least 32,083 units of Galectin Therapeutics Inc stock.
You can see the complete history of Mr. Zordani stock trades at the bottom of the page.
Richard A. Zordani serves as Independent Director of the Company. (a distributor of shipping, packaging and industrial supplies) since 2013. Prior to joining Uline, Mr. Zordani served as a Director and Vice President for Diversified Financial Management Corp. (Pritzker family office) where he advised on complex legal and tax structures for domestic and foreign entities and trusts from 2003 through 2013 and an Audit Manager for Altschuler, Melvoin & Glasser LLP (now RSM McGladrey) from 1996 through 2003. Mr. Zordani received his undergraduate degree from the University of Illinois at Urbana/Champaign and is a Registered CPA in the state of Illinois.
Richard Zordani is 48, he's been the Independent Director of Galectin Therapeutics Inc since 2020. There are 18 older and 1 younger executives at Galectin Therapeutics Inc. The oldest executive at Galectin Therapeutics Inc is Gilbert Omenn, 79, who is the Independent Director.
Richard's mailing address filed with the SEC is C/O GALECTIN THERAPEUTICS INC., 4960 PEACHTREE INDUSTRIAL BLVD., STE 240, NORCROSS, GA, 30071.
Over the last 14 years, insiders at Galectin Therapeutics Inc have traded over $21,823,082 worth of Galectin Therapeutics Inc stock and bought 5,077,107 units worth $21,362,250 . The most active insiders traders include Richard E Uihlein, James C Czirr oraz Fund, L.P.10 X Capital Mana.... On average, Galectin Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $226,012. The most recent stock trade was executed by Richard A. Jr. Zordani on 22 August 2024, trading 3,500 units of GALT stock currently worth $8,050.
galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much
Galectin Therapeutics Inc executives and other stock owners filed with the SEC include: